{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.1","upperLimit":"74.6","value":"64.8"},{"groupId":"OG001","lowerLimit":"51.9","upperLimit":"83.7","value":"69.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"description":"Overall response rate is defined as the percentage of participants with an overall response (per the investigator assessment) 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL) National Cancer Institute-Working Group (NCI-WG) criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with ibrutinib-resistant or refractory chronic lymphocytic leukemia (CLL) in the Main and Expansion Cohorts","id":"OG000","title":"ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts"},{"description":"Participants with idelalisib-resistant or refractory chronic lymphocytic leukemia (CLL) in the Main and Expansion Cohorts","id":"OG001","title":"ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts"}],"paramType":"NUMBER","populationDescription":"All participants in the Main and Expansion Cohorts who received at least one dose of venetoclax","reportingStatus":"POSTED","timeFrame":"At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort","title":"Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}